VTD-PACE regimen
WikiDoc Resources for VTD-PACE regimen |
Articles |
---|
Most recent articles on VTD-PACE regimen Most cited articles on VTD-PACE regimen |
Media |
Powerpoint slides on VTD-PACE regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on VTD-PACE regimen at Clinical Trials.gov Trial results on VTD-PACE regimen Clinical Trials on VTD-PACE regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on VTD-PACE regimen NICE Guidance on VTD-PACE regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on VTD-PACE regimen Discussion groups on VTD-PACE regimen Patient Handouts on VTD-PACE regimen Directions to Hospitals Treating VTD-PACE regimen Risk calculators and risk factors for VTD-PACE regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for VTD-PACE regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
VTD-PACE regimen refers to a regimen consisting of bortezomib (Velcade), thalidomide, dexamethasone, Platinum (cisplatin), Adriamycin (doxorubicin), cyclophosphamide, etoposide used to treat multiple myeloma.[1]
Regimen
VBortezomib (Velcade)
TThalidomide
DDexamethasone
PPlatinum (cisplatin)
AAdriamycin (doxorubicin)
CCyclophosphamide
EEtoposide
Indications
References
- ↑ 1.0 1.1 Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M; et al. (2007). "Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3". Br J Haematol. 138 (2): 176–85. doi:10.1111/j.1365-2141.2007.06639.x. PMID 17593024.